Glaucoma screening: where are we and where do we need to go?

PURPOSE OF REVIEWCurrent recommendations for glaucoma screening are decidedly neutral. No studies have yet documented improved long-term outcomes for individuals who undergo glaucoma screening versus those who do not. Given the long duration that would be required to detect a benefit, future studies...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Current opinion in ophthalmology 2020-03, Vol.31 (2), p.91-100
Hauptverfasser: Tan, Nicholas Y.Q., Friedman, David S., Stalmans, Ingeborg, Ahmed, Iqbal Ike K., Sng, Chelvin C.A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 100
container_issue 2
container_start_page 91
container_title Current opinion in ophthalmology
container_volume 31
creator Tan, Nicholas Y.Q.
Friedman, David S.
Stalmans, Ingeborg
Ahmed, Iqbal Ike K.
Sng, Chelvin C.A.
description PURPOSE OF REVIEWCurrent recommendations for glaucoma screening are decidedly neutral. No studies have yet documented improved long-term outcomes for individuals who undergo glaucoma screening versus those who do not. Given the long duration that would be required to detect a benefit, future studies that may answer this question definitively are unlikely. Nevertheless, advances in artificial intelligence and telemedicine will lead to more effective screening at lower cost. With these new technologies, additional research is needed to determine the costs and benefits of screening for glaucoma. RECENT FINDINGSUsing optic disc photographs and/or optical coherence tomography, deep learning systems appear capable of diagnosing glaucoma more accurately than human graders. Eliminating the need for expert graders along with better technologies for remote imaging of the ocular fundus will allow for less expensive screening, which could enable screening of individuals with otherwise limited healthcare access. In India and China, where most glaucoma remains undiagnosed, glaucoma screening was recently found to be cost-effective. SUMMARYRecent advances in artificial intelligence and telemedicine have the potential to increase the accuracy, reduce the costs, and extend the reach of screening. Further research into implementing these technologies in glaucoma screening is required.
doi_str_mv 10.1097/ICU.0000000000000649
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2333933082</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2333933082</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4679-61b454cb94df9e5483446322a0999c8b6f0d6f5fd556e3c19ace861d889a61ce3</originalsourceid><addsrcrecordid>eNqFkF1LwzAUhoMoTqf_QKSX3nQmzUcTEUSGzsHAG3cd0vR0m3bNTFqK_96MTREv9MDhfPC858CL0AXBI4JVfj0dz0f4ZwimDtAJ4ZSkOc7IYewxw6nMqRyg0xBeI8Ow5MdoQInCjCtxgm4ntemsW5skWA_QrJrFTdIvwUNiYvaxNOV-Ubrt3ACUSeuShbs7Q0eVqQOc7-sQzR8fXsZP6ex5Mh3fz1LLRK5SQQrGmS0UKysFnEnKmKBZZrBSyspCVLgUFa9KzgVQS5SxIAUppVRGEAt0iK52dzfevXcQWr1eBQt1bRpwXdAZpVRRimUWUbZDrXcheKj0xq_Wxn9ogvXWNx190799i7LL_YeuWEP5LfoyKgJyB_SubsGHt7rrweslmLpd_neb_SGNEOc55WmGM4xpHNOtkNFPvzmGkQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2333933082</pqid></control><display><type>article</type><title>Glaucoma screening: where are we and where do we need to go?</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Tan, Nicholas Y.Q. ; Friedman, David S. ; Stalmans, Ingeborg ; Ahmed, Iqbal Ike K. ; Sng, Chelvin C.A.</creator><creatorcontrib>Tan, Nicholas Y.Q. ; Friedman, David S. ; Stalmans, Ingeborg ; Ahmed, Iqbal Ike K. ; Sng, Chelvin C.A.</creatorcontrib><description>PURPOSE OF REVIEWCurrent recommendations for glaucoma screening are decidedly neutral. No studies have yet documented improved long-term outcomes for individuals who undergo glaucoma screening versus those who do not. Given the long duration that would be required to detect a benefit, future studies that may answer this question definitively are unlikely. Nevertheless, advances in artificial intelligence and telemedicine will lead to more effective screening at lower cost. With these new technologies, additional research is needed to determine the costs and benefits of screening for glaucoma. RECENT FINDINGSUsing optic disc photographs and/or optical coherence tomography, deep learning systems appear capable of diagnosing glaucoma more accurately than human graders. Eliminating the need for expert graders along with better technologies for remote imaging of the ocular fundus will allow for less expensive screening, which could enable screening of individuals with otherwise limited healthcare access. In India and China, where most glaucoma remains undiagnosed, glaucoma screening was recently found to be cost-effective. SUMMARYRecent advances in artificial intelligence and telemedicine have the potential to increase the accuracy, reduce the costs, and extend the reach of screening. Further research into implementing these technologies in glaucoma screening is required.</description><identifier>ISSN: 1040-8738</identifier><identifier>EISSN: 1531-7021</identifier><identifier>DOI: 10.1097/ICU.0000000000000649</identifier><identifier>PMID: 31904596</identifier><language>eng</language><publisher>United States: Wolters Kluwer Health, Inc. All rights reserved</publisher><subject>Artificial Intelligence ; Cost-Benefit Analysis ; Deep Learning ; Diagnostic Techniques, Ophthalmological ; Economics, Medical ; Glaucoma - diagnosis ; Humans ; Telemedicine ; Tomography, Optical Coherence - methods</subject><ispartof>Current opinion in ophthalmology, 2020-03, Vol.31 (2), p.91-100</ispartof><rights>Wolters Kluwer Health, Inc. All rights reserved.</rights><rights>Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4679-61b454cb94df9e5483446322a0999c8b6f0d6f5fd556e3c19ace861d889a61ce3</citedby><cites>FETCH-LOGICAL-c4679-61b454cb94df9e5483446322a0999c8b6f0d6f5fd556e3c19ace861d889a61ce3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31904596$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tan, Nicholas Y.Q.</creatorcontrib><creatorcontrib>Friedman, David S.</creatorcontrib><creatorcontrib>Stalmans, Ingeborg</creatorcontrib><creatorcontrib>Ahmed, Iqbal Ike K.</creatorcontrib><creatorcontrib>Sng, Chelvin C.A.</creatorcontrib><title>Glaucoma screening: where are we and where do we need to go?</title><title>Current opinion in ophthalmology</title><addtitle>Curr Opin Ophthalmol</addtitle><description>PURPOSE OF REVIEWCurrent recommendations for glaucoma screening are decidedly neutral. No studies have yet documented improved long-term outcomes for individuals who undergo glaucoma screening versus those who do not. Given the long duration that would be required to detect a benefit, future studies that may answer this question definitively are unlikely. Nevertheless, advances in artificial intelligence and telemedicine will lead to more effective screening at lower cost. With these new technologies, additional research is needed to determine the costs and benefits of screening for glaucoma. RECENT FINDINGSUsing optic disc photographs and/or optical coherence tomography, deep learning systems appear capable of diagnosing glaucoma more accurately than human graders. Eliminating the need for expert graders along with better technologies for remote imaging of the ocular fundus will allow for less expensive screening, which could enable screening of individuals with otherwise limited healthcare access. In India and China, where most glaucoma remains undiagnosed, glaucoma screening was recently found to be cost-effective. SUMMARYRecent advances in artificial intelligence and telemedicine have the potential to increase the accuracy, reduce the costs, and extend the reach of screening. Further research into implementing these technologies in glaucoma screening is required.</description><subject>Artificial Intelligence</subject><subject>Cost-Benefit Analysis</subject><subject>Deep Learning</subject><subject>Diagnostic Techniques, Ophthalmological</subject><subject>Economics, Medical</subject><subject>Glaucoma - diagnosis</subject><subject>Humans</subject><subject>Telemedicine</subject><subject>Tomography, Optical Coherence - methods</subject><issn>1040-8738</issn><issn>1531-7021</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkF1LwzAUhoMoTqf_QKSX3nQmzUcTEUSGzsHAG3cd0vR0m3bNTFqK_96MTREv9MDhfPC858CL0AXBI4JVfj0dz0f4ZwimDtAJ4ZSkOc7IYewxw6nMqRyg0xBeI8Ow5MdoQInCjCtxgm4ntemsW5skWA_QrJrFTdIvwUNiYvaxNOV-Ubrt3ACUSeuShbs7Q0eVqQOc7-sQzR8fXsZP6ex5Mh3fz1LLRK5SQQrGmS0UKysFnEnKmKBZZrBSyspCVLgUFa9KzgVQS5SxIAUppVRGEAt0iK52dzfevXcQWr1eBQt1bRpwXdAZpVRRimUWUbZDrXcheKj0xq_Wxn9ogvXWNx190799i7LL_YeuWEP5LfoyKgJyB_SubsGHt7rrweslmLpd_neb_SGNEOc55WmGM4xpHNOtkNFPvzmGkQ</recordid><startdate>20200301</startdate><enddate>20200301</enddate><creator>Tan, Nicholas Y.Q.</creator><creator>Friedman, David S.</creator><creator>Stalmans, Ingeborg</creator><creator>Ahmed, Iqbal Ike K.</creator><creator>Sng, Chelvin C.A.</creator><general>Wolters Kluwer Health, Inc. All rights reserved</general><general>Copyright Wolters Kluwer Health, Inc. All rights reserved</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20200301</creationdate><title>Glaucoma screening: where are we and where do we need to go?</title><author>Tan, Nicholas Y.Q. ; Friedman, David S. ; Stalmans, Ingeborg ; Ahmed, Iqbal Ike K. ; Sng, Chelvin C.A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4679-61b454cb94df9e5483446322a0999c8b6f0d6f5fd556e3c19ace861d889a61ce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Artificial Intelligence</topic><topic>Cost-Benefit Analysis</topic><topic>Deep Learning</topic><topic>Diagnostic Techniques, Ophthalmological</topic><topic>Economics, Medical</topic><topic>Glaucoma - diagnosis</topic><topic>Humans</topic><topic>Telemedicine</topic><topic>Tomography, Optical Coherence - methods</topic><toplevel>online_resources</toplevel><creatorcontrib>Tan, Nicholas Y.Q.</creatorcontrib><creatorcontrib>Friedman, David S.</creatorcontrib><creatorcontrib>Stalmans, Ingeborg</creatorcontrib><creatorcontrib>Ahmed, Iqbal Ike K.</creatorcontrib><creatorcontrib>Sng, Chelvin C.A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current opinion in ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tan, Nicholas Y.Q.</au><au>Friedman, David S.</au><au>Stalmans, Ingeborg</au><au>Ahmed, Iqbal Ike K.</au><au>Sng, Chelvin C.A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Glaucoma screening: where are we and where do we need to go?</atitle><jtitle>Current opinion in ophthalmology</jtitle><addtitle>Curr Opin Ophthalmol</addtitle><date>2020-03-01</date><risdate>2020</risdate><volume>31</volume><issue>2</issue><spage>91</spage><epage>100</epage><pages>91-100</pages><issn>1040-8738</issn><eissn>1531-7021</eissn><abstract>PURPOSE OF REVIEWCurrent recommendations for glaucoma screening are decidedly neutral. No studies have yet documented improved long-term outcomes for individuals who undergo glaucoma screening versus those who do not. Given the long duration that would be required to detect a benefit, future studies that may answer this question definitively are unlikely. Nevertheless, advances in artificial intelligence and telemedicine will lead to more effective screening at lower cost. With these new technologies, additional research is needed to determine the costs and benefits of screening for glaucoma. RECENT FINDINGSUsing optic disc photographs and/or optical coherence tomography, deep learning systems appear capable of diagnosing glaucoma more accurately than human graders. Eliminating the need for expert graders along with better technologies for remote imaging of the ocular fundus will allow for less expensive screening, which could enable screening of individuals with otherwise limited healthcare access. In India and China, where most glaucoma remains undiagnosed, glaucoma screening was recently found to be cost-effective. SUMMARYRecent advances in artificial intelligence and telemedicine have the potential to increase the accuracy, reduce the costs, and extend the reach of screening. Further research into implementing these technologies in glaucoma screening is required.</abstract><cop>United States</cop><pub>Wolters Kluwer Health, Inc. All rights reserved</pub><pmid>31904596</pmid><doi>10.1097/ICU.0000000000000649</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1040-8738
ispartof Current opinion in ophthalmology, 2020-03, Vol.31 (2), p.91-100
issn 1040-8738
1531-7021
language eng
recordid cdi_proquest_miscellaneous_2333933082
source MEDLINE; Journals@Ovid Complete
subjects Artificial Intelligence
Cost-Benefit Analysis
Deep Learning
Diagnostic Techniques, Ophthalmological
Economics, Medical
Glaucoma - diagnosis
Humans
Telemedicine
Tomography, Optical Coherence - methods
title Glaucoma screening: where are we and where do we need to go?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T02%3A09%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Glaucoma%20screening:%20where%20are%20we%20and%20where%20do%20we%20need%20to%20go?&rft.jtitle=Current%20opinion%20in%20ophthalmology&rft.au=Tan,%20Nicholas%20Y.Q.&rft.date=2020-03-01&rft.volume=31&rft.issue=2&rft.spage=91&rft.epage=100&rft.pages=91-100&rft.issn=1040-8738&rft.eissn=1531-7021&rft_id=info:doi/10.1097/ICU.0000000000000649&rft_dat=%3Cproquest_cross%3E2333933082%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2333933082&rft_id=info:pmid/31904596&rfr_iscdi=true